Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Sarah T. Diepstraten"'
Autor:
Yexuan Deng, Sarah T. Diepstraten, Margaret A. Potts, Göknur Giner, Stephanie Trezise, Ashley P. Ng, Gerry Healey, Serena R. Kane, Amali Cooray, Kira Behrens, Amy Heidersbach, Andrew J. Kueh, Martin Pal, Stephen Wilcox, Lin Tai, Warren S. Alexander, Jane E. Visvader, Stephen L. Nutt, Andreas Strasser, Benjamin Haley, Quan Zhao, Gemma L. Kelly, Marco J. Herold
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-17 (2022)
Modelling of aggressive lymphomas, such as double hit lymphoma, has been challenging. Here the authors engineer a CRISPR activation mouse to enable the generation of these aggressive lymphomas and identify the pro-survival BCL-2 protein A1 as a venet
Externí odkaz:
https://doaj.org/article/a6a1367d102e4deb8dbd0ddb559ac31c
Autor:
John E. La Marca, Robert W. Ely, Sarah T. Diepstraten, Peter Burke, Gemma L. Kelly, Patrick O. Humbert, Helena E. Richardson
Publikováno v:
Disease Models & Mechanisms, Vol 16, Iss 3 (2023)
Externí odkaz:
https://doaj.org/article/e9522fc36290440fb2985f54b8531064
Autor:
Yexuan Deng, Sarah T. Diepstraten, Margaret A. Potts, Göknur Giner, Stephanie Trezise, Ashley P. Ng, Gerry Healey, Serena R. Kane, Amali Cooray, Kira Behrens, Amy Heidersbach, Andrew J. Kueh, Martin Pal, Stephen Wilcox, Lin Tai, Warren S. Alexander, Jane E. Visvader, Stephen L. Nutt, Andreas Strasser, Benjamin Haley, Quan Zhao, Gemma L. Kelly, Marco J. Herold
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-1 (2022)
Externí odkaz:
https://doaj.org/article/cc4c296b2b374573b5cc8009f758bbc9
Autor:
Sarah T. Diepstraten, Savannah Young, John E. La Marca, Zilu Wang, Ruth M. Kluck, Andreas Strasser, Gemma L. Kelly
Publikováno v:
Cell Death & Differentiation. 30:1005-1017
BH3-mimetic drugs are an anti-cancer therapy that can induce apoptosis in malignant cells by directly binding and inhibiting pro-survival proteins of the BCL-2 family. The BH3-mimetic drug venetoclax, which targets BCL-2, has been approved for the tr
Autor:
Zilu Wang, Huimin Hu, Luuk Heitink, Kelly Rogers, Yue You, Tao Tan, Connie Li Wai Suen, Alex Garnham, Hao Chen, Elizabeth Lieschke, Sarah T. Diepstraten, Catherine Chang, Tianwei Chen, Diane Moujalled, Kate Sutherland, Guillaume Lessene, Oliver M. Sieber, Jane Visvader, Gemma L. Kelly, Andreas Strasser
Publikováno v:
Cell Death & Differentiation. 30:1033-1046
Mutant TP53 proteins are thought to drive the development and sustained expansion of cancers at least in part through the loss of the wild-type (wt) TP53 tumour suppressive functions. Therefore, compounds that can restore wt TP53 functions in mutant
Publikováno v:
Biochemical Society Transactions. 50:1119-1128
BFL-1 is an understudied pro-survival BCL-2 protein. The expression of BFL-1 is reported in many cancers, but it is yet to be clarified whether high transcript expression also always correlates with a pro-survival function. However, recent applicatio
Autor:
Andreas Strasser, Mary Ann Anderson, Guillaume Lessene, Peter E. Czabotar, Sarah T Diepstraten, Gemma L. Kelly
Publikováno v:
Nature Reviews Cancer. 22:45-64
Apoptosis is a form of programmed cell death that is regulated by the balance between prosurvival and proapoptotic BCL-2 protein family members. Evasion of apoptosis is a hallmark of cancer that arises when this balance is tipped in favour of surviva
Publikováno v:
Apoptosis : an international journal on programmed cell death.
Acquired resistance to cell death is a hallmark of cancer. The BCL-2 protein family members play important roles in controlling apoptotic cell death. Abnormal over-expression of pro-survival BCL-2 family members or abnormal reduction of pro-apoptotic
Autor:
Sarah T. Diepstraten, Flavia Iannizzotto, Richard B. Pearson, Gemma L. Kelly, Ramon Salazar, Joffrey Pelletier, Carol A. Mercer, Marta Garcia-Cajide, Sara C. Kozma, Suresh Peddigari, George Thomas, Antonio Gentilella, Marta Leonor Rodríguez, Eric P Kusnadi, Jian Kang, Virginia Amador, Ana Domostegui
Publikováno v:
Blood. 137:3351-3364
MYC-driven B-cell lymphomas are addicted to increased levels of ribosome biogenesis (RiBi), offering the potential for therapeutic intervention. However, it is unclear whether inhibition of RiBi suppresses lymphomagenesis by decreasing translational
Autor:
Brandon J. Aubrey, Margs S. Brennan, Sarah T. Diepstraten, Zilu Wang, Catherine Chang, Marco J. Herold, Andreas Strasser, Gemma L. Kelly
Publikováno v:
Cell Death Differ